GlassScriptPhysician profile
Alyssa Sheffield
NPI 1326704537
$5,752.51
in general payments reported to CMS, 2019-2025
43 companies · $1,279 in 2025
The $1,279 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.89 · 2022: $583 · 2023: $1,565 · 2024: $2,304 · 2025: $1,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,304 · Education: $844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,303.68 |
| Education | $843.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $570.72 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $443.98 | 2022-2025 | Imfinzi, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $364.03 | 2022-2025 | Opdivo, Opdualag |
| Sobi, INC | $351.24 | 2022-2025 | |
| Astellas Pharma US INC | $346.95 | 2023-2025 | Padcev, Xtandi, Xospata |
| Seagen INC. | $346.54 | 2022-2025 | Padcev |
| Merck Sharp & Dohme LLC | $305.97 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $274.88 | 2023-2025 | Enhertu |
| Pfizer INC. | $270.93 | 2024-2025 | |
| Celgene Corporation | $260.57 | 2023-2025 | Pomalyst, Opdualag, Opdivo |
| Tempus Ai, INC | $229.16 | 2024-2025 | Xt Cdx |
| Mirati Therapeutics, INC. | $161.93 | 2023-2024 | Krazati |
| Amgen INC. | $152.10 | 2021-2023 | Lumakras |
| Glaxosmithkline, LLC. | $125.82 | 2023-2024 | Ojjaara, Jemperli, Zejula |
| Lilly USA, LLC | $106.15 | 2023-2025 | Jaypirca, Verzenio |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $96.89 | 2024-2025 | Rybrevant, Imbruvica, Darzalex |
| Pharmacyclics LLC, An Abbvie Company | $92.20 | 2022-2023 | Imbruvica |
| Aveo Pharmaceuticals, INC. | $88.29 | 2023-2025 | Fotivda |
| Genzyme Corporation | $85.35 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $83.88 | 2024 | Onivyde, Somatuline Depot |
| Beigene USA, INC. | $80.53 | 2023-2024 | Brukinsa |
| Genentech USA, INC. | $75.59 | 2024-2025 | Tecentriq, Alecensa, Rozlytrek |
| Grifols USA, LLC | $72.92 | 2023 | Gamunex-C |
| Emd Serono, INC. | $70.74 | 2023-2024 | Bavencio |
| Taiho Oncology, INC. | $70.59 | 2024-2025 | |
| Cti Biopharma Corp. | $70.43 | 2022-2023 | Vonjo |
| Sumitomo Pharma America, INC. | $59.25 | 2024-2025 | Orgovyx, Myfembree |
| Regeneron Healthcare Solutions, INC. | $58.68 | 2023-2025 | Libtayo |
| Alexion Pharmaceuticals, INC. | $58.39 | 2022-2023 | Ultomiris |
| Myriad Genetic Laboratories, INC. | $53.87 | 2023-2024 | Prolaris, Myrisk, Mychoice Cdx |
| Abbvie INC. | $51.73 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $43.43 | 2024 | |
| Karyopharm Therapeutics INC. | $36.10 | 2023 | Xpovio |
| Immunocore Limited | $25.16 | 2024 | Kimmtrak |
| Puma Biotechnology, INC. | $22.75 | 2023 | |
| Azurity Pharmaceuticals, INC. | $22.71 | 2024 | Vivimusta |
| Beone Medicines USA, INC. | $19.43 | 2025 | Brukinsa |
| Telix Pharmaceuticals | $17.96 | 2023 | Illuccix |
| Sirtex Medical INC | $17.83 | 2023 | Sir-Spheres Microspheres |
| Pharmaessentia USA Corporation | $17.27 | 2023 | Besremi |
| Pharmacosmos Therapeutics INC. | $16.96 | 2024 | Monoferric |
| Tersera Therapeutics LLC | $16.60 | 2025 | Xermelo |
| Geron Corporation | $16.01 | 2025 | Rytelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Sheffield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.